NovaScan has proven empirically that its Cole frequency technology can not only inform on the presence of cancer, but can also inform on the aggressiveness of cancer and the predisposition of metastasis. In a retrospective study of breast cancer patients, NovaScan correlated its assessment of the Cole frequency completed at the point of surgery with long term surgical outcomes. The results were consistent with the theory and were striking. Those patients with Cole frequencies between 1*10^5 and 3*10^5 had no recurrences, independent of the stage of cancer at the time of surgery or even the adjunctive therapies employed. Some of the patients with Cole frequencies between 3*10^5 and 6*10^5 had recurrences, with the recurrences becoming more likely and faster in the higher end of this range. Patients with Cole frequencies above 6*10^5 had poor outcomes; most of the patients recurred rapidly and metastatically.
In essence, NovaScan has demonstrated that measurement of the Cole frequency – which can be completed at the time of biopsy – can inform on the presence of cancer and can help drive surgical decision making, much like a genetic test. However, NovaScan’s results are both 1.) available in real time and 2.) broadly applicable, independent of cancer genetics.